CN108440365A - 多取代吡咯衍生物的制备方法 - Google Patents
多取代吡咯衍生物的制备方法 Download PDFInfo
- Publication number
- CN108440365A CN108440365A CN201810685651.7A CN201810685651A CN108440365A CN 108440365 A CN108440365 A CN 108440365A CN 201810685651 A CN201810685651 A CN 201810685651A CN 108440365 A CN108440365 A CN 108440365A
- Authority
- CN
- China
- Prior art keywords
- pyrrole derivative
- catalyst
- oxygen
- polysubstituted pyrrole
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003233 pyrroles Chemical class 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000001301 oxygen Substances 0.000 claims abstract description 34
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 34
- 238000006243 chemical reaction Methods 0.000 claims abstract description 26
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 17
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229950002366 nafoxidine Drugs 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003054 catalyst Substances 0.000 claims abstract description 11
- 239000007800 oxidant agent Substances 0.000 claims abstract description 9
- 150000003254 radicals Chemical class 0.000 claims abstract description 9
- 239000003426 co-catalyst Substances 0.000 claims abstract description 8
- 230000001590 oxidative effect Effects 0.000 claims abstract description 8
- 229910052802 copper Inorganic materials 0.000 claims abstract description 6
- 239000010949 copper Substances 0.000 claims abstract description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 4
- -1 carbomethoxyphenyl Chemical group 0.000 claims description 35
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- 238000004440 column chromatography Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 229910021589 Copper(I) bromide Inorganic materials 0.000 claims description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 6
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 5
- 150000001879 copper Chemical class 0.000 claims description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical class ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 4
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 claims description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 3
- 206010011224 Cough Diseases 0.000 claims description 3
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims description 3
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical group [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 claims description 3
- YRNNKGFMTBWUGL-UHFFFAOYSA-L copper(ii) perchlorate Chemical compound [Cu+2].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O YRNNKGFMTBWUGL-UHFFFAOYSA-L 0.000 claims description 3
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- PNGLEYLFMHGIQO-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methoxyanilino)-2-hydroxypropane-1-sulfonate;dihydrate Chemical compound O.O.[Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(OC)=C1 PNGLEYLFMHGIQO-UHFFFAOYSA-M 0.000 claims description 3
- MFYLRNKOXORIPK-UHFFFAOYSA-N (3-nitrophenyl)-phenylmethanone Chemical class [O-][N+](=O)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 MFYLRNKOXORIPK-UHFFFAOYSA-N 0.000 claims description 2
- UJVWPZIWWKDJNH-UHFFFAOYSA-N (4-acetamido-2-hydroxyphenyl)arsonic acid Chemical compound CC(=O)NC1=CC=C([As](O)(O)=O)C(O)=C1 UJVWPZIWWKDJNH-UHFFFAOYSA-N 0.000 claims description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N 1-nonene Chemical compound CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 2
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 claims description 2
- 239000005751 Copper oxide Substances 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 229910000431 copper oxide Inorganic materials 0.000 claims description 2
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 238000001953 recrystallisation Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- DOTMOQHOJINYBL-UHFFFAOYSA-N molecular nitrogen;molecular oxygen Chemical compound N#N.O=O DOTMOQHOJINYBL-UHFFFAOYSA-N 0.000 claims 2
- VDVUCLWJZJHFAV-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidin-4-ol Chemical class CC1(C)CC(O)CC(C)(C)N1 VDVUCLWJZJHFAV-UHFFFAOYSA-N 0.000 claims 1
- JKWMFVLOTXOKIR-UHFFFAOYSA-N C(=O)=C1CC(NC(C1)(C)C)(C)C Chemical class C(=O)=C1CC(NC(C1)(C)C)(C)C JKWMFVLOTXOKIR-UHFFFAOYSA-N 0.000 claims 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical class COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 19
- 238000000034 method Methods 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 5
- 238000003912 environmental pollution Methods 0.000 abstract description 4
- 239000006227 byproduct Substances 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 239000000575 pesticide Substances 0.000 abstract description 3
- 230000003197 catalytic effect Effects 0.000 abstract description 2
- 230000001681 protective effect Effects 0.000 abstract 1
- 239000012043 crude product Substances 0.000 description 16
- 238000004809 thin layer chromatography Methods 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 11
- 150000007980 azole derivatives Chemical class 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000005311 nuclear magnetism Effects 0.000 description 5
- 150000003235 pyrrolidines Chemical class 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000002360 explosive Substances 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 2
- QSHWIQZFGQKFMA-UHFFFAOYSA-N porphobilinogen Chemical compound NCC=1NC=C(CCC(O)=O)C=1CC(O)=O QSHWIQZFGQKFMA-UHFFFAOYSA-N 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- KFUSEUYYWQURPO-UHFFFAOYSA-N 1,2-dichloroethene Chemical compound ClC=CCl KFUSEUYYWQURPO-UHFFFAOYSA-N 0.000 description 1
- ADVWVIQNAOXLCV-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperazine Chemical class CC1(C)CNCC(C)(C)N1 ADVWVIQNAOXLCV-UHFFFAOYSA-N 0.000 description 1
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- DYDNPESBYVVLBO-UHFFFAOYSA-N formanilide Chemical compound O=CNC1=CC=CC=C1 DYDNPESBYVVLBO-UHFFFAOYSA-N 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyrrole Compounds (AREA)
Abstract
本发明公开了一种多取代吡咯衍生物的制备方法,以铜盐为催化剂、氮氧自由基为共催化剂,以来自于空气中的氧气为最终氧化剂,从四氢吡咯出发制备得多取代吡咯衍生物。本发明的工艺流程中仅需使用催化量的铜催化剂和非金属的共催化剂,且所用的氧化剂价格低廉、唯一的副产物是水,后处理工艺流程更加简单,明显降低了环境污染风险;整个流程在氧气气氛下进行,且对湿气不敏感,可在宽松的反应条件下作常规操作;可为生物、农药和医药领域制备相关产品,以绿色环保的方式提供来源充裕、价格较低的多取代吡咯衍生物。
Description
技术领域
本发明属于有机合成领域,具体涉及吡咯衍生物的制备方法,特别涉及一种多取代吡咯衍生物的制备方法。
背景技术
吡咯衍生物广泛应用于生物、农药、医药和有机半导体材料领域,是生产药物、染料和有机半导体材料的中间体。例如:它是胆色素原、血红素和叶绿素的关键结构单元;另外,它是降压降脂药物阿伐他汀和止痛药消炎药酮咯酸的核心结构单元;它是合成具有重要生理活性生物碱的关键中间体。近些年来有研究证实,吡咯衍生物的生物活性,为人类在抗肿瘤、抗菌、抗病毒、杀螨虫、抗炎、抗心律失常、抗高血压等方面也发挥有积极作用。其中,多取代吡咯衍生物是吡咯衍生物中的一种重要合成物。然而,现有技术中从四氢吡咯出发合成多取代吡咯衍生物,都需要使用等当量甚至过量的过渡金属或其它高毒性或易爆的氧化剂,如二氧化锰、二氯二氰基苯醌(DDQ)等。现有技术存在以下不足之处:一是所使用的氧化剂用量大、价格昂贵,从而导致生产成本大大增加;二是使用的氧化剂毒性大或是易爆品,且生成大量的还原副产物,导致环境污染和安全风险高企。
发明内容
鉴于上述现有技术存在的缺陷,本发明的目的在于提供一种多取代吡咯衍生物的制备方法,能够降低生产成本,同时极大的降低环境污染风险。
本发明是通过以下技术方案实现的:
多取代吡咯衍生物的制备方法,利用四氢吡咯为原料,以铜盐和氮氧自由基为催化剂,氧气为最终氧化剂,制备得多取代吡咯衍生物;反应方程式如下:
具体包括如下步骤:
1)将四氢吡咯、铜盐催化剂、氮氧自由基共催化剂置入反应器皿中,加入溶剂。所述四氢吡咯、铜盐催化剂、氮氧自由基共催化剂的摩尔比为1:0.05~0.20:0.05~0.30;
2)在氧气气氛下,于70~110摄氏度下加热搅拌至反应结束,反应时间2~24小时;
3)将反应后的混合物倒入水中,经过滤、洗涤、干燥后重结晶或柱层析分离,得到的油状物或固体物即为目标产物多取代吡咯衍生物。
本发明进一步方案为:
所述四氢吡咯化学式中R1为苯基、2-甲基苯基、3-甲基苯基、4-甲基苯基、4-碳酰甲酯基苯基、4-N,N-二甲氨基苯基、4-氯苯基、4-溴苯基、4-甲氧基苯基、3-硝基苯基、3-氰基苯基、苄基、4-甲氧基苄基、丁基、叔丁基、环己基、正戊基、3-吡啶基、2-噻吩基、5-甲基-2-呋喃基或2-苯基乙基; R2为甲基、乙基或丁基;R3为氢、甲基、乙基、苯基、2-氯苯基、3-氯苯基、4-氯苯基、4-甲氧基苯基、3-碳酰甲酯基苯基、碳酰甲酯基、碳酰丁酯基或碳酰乙酯基;EWG为氰基、苯甲酰基、4-硝基苯基酰基、2-氯苯甲酰基、3-氯苯甲酰基、4-氯苯甲酰基、4-甲基苯甲酰基、4-甲氧基苯甲酰基、乙酰基、丙酰基、膦酰二甲酯基、碳酰甲酯基、碳酰丁酯基或碳酰乙酯基。
所述铜盐催化剂为醋酸铜、溴化亚铜、氧化铜、硝酸铜、高氯酸铜、六氟磷酸四乙腈合亚铜、三氟甲磺酸铜或2-乙基己酸铜。
所述氮氧自由基共催化剂为2,2,6,6-四甲基哌啶-N-氧自由基、4-羟基-2,2,6,6-四甲基哌啶-N-氧自由基、4-乙酰氨基-2,2,6,6-四甲基哌啶-N-氧自由基、4-羰基-2,2,6,6-四甲基哌啶-N-氧自由基或9-氮杂二环[3.3.1]壬烷-N-氧自由基。
所述溶剂为乙酸乙酯、四氢呋喃、环己烷、1,2-二氯乙烷、碳酸二甲酯或苯。
本发明的有益效果:
本发明利用四氢吡咯为原料,以铜盐和氮氧自由基为催化剂,以氧气为最终氧化剂,制备得多取代吡咯衍生物,大大降低了现有技术制备多取代吡咯衍生物的合成成本;工艺流程中仅需使用催化量的铜盐和氮氧自由基催化剂,以来自空气中的氧气为最终氧化剂,唯一的还原副产物是水,后处理工艺流程更加简单,极大的降低了环境污染风险;整个流程对湿气都不敏感,可在宽松的反应条件作常规操作;可为生物、农药、材料和医药等领域制备相关产品,提供来源充裕、价格较低的多取代吡咯衍生物。
附图说明
附图1为本发明方法工艺流程框图;
附图2为本发明实施例一所得目标产物的核磁氢谱图;
附图3为本发明实施例一所得目标产物的核磁碳谱图;
附图4为本发明实施例五所得目标产物的核磁氢谱图;
附图5为本发明实施例五所得目标产物的核磁碳谱图;
本发明实施例二、三、四、六、七、八所得目标产物的核磁氢谱图和核磁碳谱图限于篇幅,未列入附图中。
具体实施方式
实施例一
如附图1的工艺流程,取四氢吡咯5-(4-甲氧基苯基)-吡咯烷-2,3,4-三甲酸甲酯70.3毫克(相当于0.20毫摩尔),溴化亚铜2.9毫克(相当于0.02毫摩尔),2,2,6,6-四甲基哌啶-N-氧自由基3.1毫克(相当于0.02毫摩尔)和1.0毫升1,2-二氯乙烷加入反应容器中,在氧气气氛下,于 80摄氏度加热搅拌5小时,通过薄层层析(TLC点板)分析,至反应完全。上述所得混合物倒入水中,经过滤、洗涤、干燥得粗产品。粗产品经柱层析分离得到本实施例目标产物多取代吡咯衍生物59.8毫克(得率为86%)。
本实施例一的目标产物,经核磁共振波谱仪(型号:AVANCE 400MHz,生产商:瑞士布鲁克)分析,获得图2所示的的核磁氢谱和图3所示的核磁碳谱。前者其参数为1H NMR(CDCl3,400MHz): 9.77 – 9.53 (m, 1H), 7.50 (d, J = 8.7Hz, 2H), 6.93 (d, J =8.8Hz, 2H), 3.94 (s, 3H), 3.83 (s, 3H), 3.79 (d, J = 5.5 Hz, 3H), 3.71 (s,3H);后者其参数为13 C NMR (CDCl3, 100 MHz): 166.0, 163.3, 160.6, 160.2, 140.2,130.7, 124.9, 122.2, 119.2, 113.7, 111.7, 55.3, 52.7, 52.3, 51.5。
由此证实:实施例一目标产物多取代吡咯衍生物完全符合品质要求。
实施例二:
如附图1的工艺流程,取四氢吡咯5-环己基-3-苯基-吡咯烷-4-甲酸甲酯-2-甲酸乙酯71.9毫克(相当于0.20毫摩尔),六氟磷酸四乙腈合亚铜3.7毫克(相当于0.01毫摩尔),4-乙酰氨基-2,2,6,6-四甲基哌啶-N-氧自由基4.3毫克(相当于0.02毫摩尔)和0.8毫升苯加入反应容器中,在氧气气氛下,于 90摄氏度加热搅拌3小时,通过薄层层析(TLC点板)分析,至反应完全。上述所得混合物倒入水中,经过滤、洗涤、干燥得粗产品。粗产品经柱层析分离得到本实施例目标产物多取代吡咯衍生物53.3毫克(得率为75%)。
实施例三:
如附图1的工艺流程,取四氢吡咯3-甲基-5-戊基-吡咯烷-2,4-二甲酸甲酯71.9毫克(相当于0.20毫摩尔),醋酸铜5.4毫克(相当于0.03毫摩尔),4-羰基-2,2,6,6-四甲基哌啶-N-氧自由基5.1毫克(相当于0.03毫摩尔)和0.6毫升乙酸乙酯加入反应容器中,在氧气气氛下,于 80摄氏度加热搅拌4小时,通过薄层层析(TLC点板)分析,至反应完全。上述所得混合物倒入水中,经过滤、洗涤、干燥得粗产品。粗产品经柱层析分离得到本实施例目标产物多取代吡咯衍生物42.2毫克(得率为79%)
实施例四:
如附图1的工艺流程,取四氢吡咯5-(2-氟苯基)-吡咯烷-2-甲酸甲酯-4-甲酸丁酯64.7毫克(相当于0.20毫摩尔),高氯酸铜5.3毫克(相当于0.02毫摩尔),4-羟基-2,2,6,6-四甲基哌啶-N-氧自由基3.5毫克(相当于0.02毫摩尔)和0.6毫升乙酸乙酯加入反应容器中,在氧气气氛下,于 80摄氏度加热搅拌8小时,通过薄层层析(TLC点板)分析,至反应完全。上述所得混合物倒入水中,经过滤、洗涤、干燥得粗产品。粗产品经柱层析分离得到本实施例目标产物多取代吡咯衍生物57.5毫克(得率为90%)。
实施例五:
如附图1的工艺流程,取四氢吡咯4-苯甲酰基-5-(4-氯苯基)-3-(4-甲基苯基)-吡咯烷-2-甲酸甲酯86.8毫克(相当于0.20毫摩尔),2-乙基己酸铜5.3毫克(相当于0.015毫摩尔),2,2,6,6-四甲基哌啶-N-氧自由基3.1毫克(相当于0.02毫摩尔)和0.8毫升1,2-二氯乙烷加入反应容器中,在氧气气氛下,于 80摄氏度加热搅拌6小时,通过薄层层析(TLC点板)分析,至反应完全。上述所得混合物倒入水中,经过滤、洗涤、干燥得粗产品。粗产品经柱层析分离得到本实施例目标产物多取代吡咯衍生物66.2毫克(得率为77%)。
实施例五目标产物,经核磁共振波谱仪(型号:AVANCE 400MHz,生产商:瑞士布鲁克)分析,获得图4所示的的核磁氢谱和图5所示的核磁碳谱。前者其参数为1H NMR (CDCl3,400 MHz): 9.52 (s, 1H), 7.65 (d, J = 8.1 Hz, 2H), 7.40 (d, J = 8.5 Hz, 2H),7.34 (t, J = 7.4 Hz, 1H), 7.28 (d, J = 3.9 Hz, 2H), 7.19 (dt, J = 8.0, 3.7Hz, 4H), 7.00 (d, J = 7.7 Hz, 2H), 3.76 (s, 3H), 2.26 (s, 3H); 后者其参数为13 C NMR (CDCl3, 100 MHz): 193.8, 161.4, 138.0, 137.0, 135.1, 134.8, 133.0,132.7, 130.1, 129.8, 129.7, 129.1, 129.0, 129.0, 128.2, 128.0, 123.6, 118.9,51.6, 21.2。
实施例六:
如附图1的工艺流程,取四氢吡咯4-氰基-5-(4-甲酰甲酯基苯基)-吡咯烷-2-甲酸甲酯57.7毫克(相当于0.20毫摩尔),溴化亚铜4.3毫克(相当于0.03毫摩尔),2,2,6,6-四甲基哌啶-N-氧自由基3.1毫克(相当于0.02毫摩尔)和1.0毫升四氢呋喃加入反应容器中,在氧气气氛下,于 80摄氏度加热搅拌16小时,通过薄层层析(TLC点板)分析,至反应完全。上述所得混合物倒入水中,经过滤、洗涤、干燥得粗产品。粗产品经柱层析分离得到本实施例目标产物多取代吡咯衍生物46.1毫克(得率为81%)。
实施例七:
如附图1的工艺流程,取四氢吡咯4- (N-苯基甲酰胺基)-5-(4-甲基苯基)-吡咯烷-2-甲酸甲酯67.7毫克 (相当于0.20毫摩尔),溴化亚铜4.3毫克(相当于0.03毫摩尔),2,2,6,6-四甲基哌啶-N-氧自由基3.1毫克(相当于0.02毫摩尔)和0.7毫升碳酸二甲酯加入反应容器中,在氧气气氛下,于 80摄氏度加热搅拌10小时,通过薄层层析(TLC点板)分析,至反应完全。上述所得混合物倒入水中,经过滤、洗涤、干燥得粗产品。粗产品经柱层析分离得到本实施例目标产物多取代吡咯衍生物48.2毫克(得率为72%)。
实施例八:
如附图1的工艺流程,取四氢吡咯4- (甲酰二甲基胺基)-2-苯基-5-(2-甲基苯基)-吡咯烷-2-甲酸甲酯73.3毫克 (相当于0.20毫摩尔),溴化亚铜4.3毫克(相当于0.03毫摩尔),2,2,6,6-四甲基哌啶-N-氧自由基3.1毫克(相当于0.02毫摩尔)和0.8毫升1,2-二氯乙烷加入反应容器中,在氧气气氛下,于 80摄氏度加热搅拌8小时,通过薄层层析(TLC点板)分析,至反应完全。上述所得混合物倒入水中,经过滤、洗涤、干燥得粗产品。粗产品经柱层析分离得到本实施例目标产物多取代吡咯衍生物54.4毫克(得率为75%)。
Claims (7)
1.多取代吡咯衍生物的制备方法,其特征在于:利用四氢吡咯为原料,以铜盐和氮氧自由基为催化剂,以氧气为氧化剂,制备得多取代吡咯衍生物;反应方程式如下:
。
2.根据权利要求1所述的多取代吡咯衍生物的制备方法,其特征在于,包括如下步骤:
1)将四氢吡咯、铜盐催化剂、氮氧自由基共催化剂置入反应器皿中,加入溶剂;
2)在氧气气氛下,于70~110摄氏度下加热搅拌至反应结束,反应时间2~24小时;
3)将反应后的混合物倒入水中,经过滤、洗涤、干燥后重结晶或柱层析分离,得到的油状物或固体物即为目标产物多取代吡咯衍生物。
3.根据权利要求1或2所述的多取代吡咯衍生物的制备方法,其特征在于:所述四氢吡咯、铜盐催化剂、氮氧自由基共催化剂的摩尔比为1:0.05~0.20:0.05~0.30。
4.根据权利要求1或2所述的多取代吡咯衍生物的制备方法,其特征在于:所述四氢吡咯化学式中R1为苯基、2-甲基苯基、3-甲基苯基、4-甲基苯基、4-碳酰甲酯基苯基、4-N,N-二甲氨基苯基、4-氯苯基、4-溴苯基、4-甲氧基苯基、3-硝基苯基、3-氰基苯基、苄基、4-甲氧基苄基、丁基、叔丁基、环己基、正戊基、3-吡啶基、2-噻吩基、5-甲基-2-呋喃基或2-苯基乙基;R2为甲基、乙基或丁基;R3为氢、甲基、乙基、苯基、2-氯苯基、3-氯苯基、4-氯苯基、4-甲氧基苯基、3-碳酰甲酯基苯基、碳酰甲酯基、碳酰丁酯基或碳酰乙酯基;EWG为氰基、苯甲酰基、4-硝基苯基酰基、2-氯苯甲酰基、3-氯苯甲酰基、4-氯苯甲酰基、4-甲基苯甲酰基、4-甲氧基苯甲酰基、乙酰基、丙酰基、膦酰二甲酯基、碳酰甲酯基、碳酰丁酯基或碳酰乙酯基。
5.根据权利要求1或2所述的多取代吡咯衍生物的制备方法,其特征在于:所述铜盐催化剂为醋酸铜、溴化亚铜、氧化铜、硝酸铜、高氯酸铜、六氟磷酸四乙腈合亚铜、三氟甲磺酸铜或2-乙基己酸铜。
6.根据权利要求1或2所述的多取代吡咯衍生物的制备方法,其特征在于:所述氮氧自由基共催化剂为2,2,6,6-四甲基哌啶-N-氧自由基、4-羟基-2,2,6,6-四甲基哌啶-N-氧自由基、4-乙酰氨基-2,2,6,6-四甲基哌啶-N-氧自由基、4-羰基-2,2,6,6-四甲基哌啶-N-氧自由基或9-氮杂二环[3.3.1]壬烷-N-氧自由基。
7.根据权利要求1或2所述的多取代吡咯衍生物的制备方法,其特征在于:所述溶剂为乙酸乙酯、四氢呋喃、环己烷、1,2-二氯乙烷、碳酸二甲酯或苯。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810685651.7A CN108440365B (zh) | 2018-06-28 | 2018-06-28 | 多取代吡咯衍生物的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810685651.7A CN108440365B (zh) | 2018-06-28 | 2018-06-28 | 多取代吡咯衍生物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108440365A true CN108440365A (zh) | 2018-08-24 |
CN108440365B CN108440365B (zh) | 2021-10-29 |
Family
ID=63207366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810685651.7A Active CN108440365B (zh) | 2018-06-28 | 2018-06-28 | 多取代吡咯衍生物的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108440365B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110357801A (zh) * | 2019-07-23 | 2019-10-22 | 浙江工业大学 | 一种碘催化三组分反应合成含氮五元杂环化合物的方法 |
CN110759909A (zh) * | 2019-11-19 | 2020-02-07 | 淮阴师范学院 | 一种吡咯并[2,1-a]异喹啉衍生物的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106749235A (zh) * | 2016-12-01 | 2017-05-31 | 西南大学 | 多取代喹啉并吡咯衍生物的制备方法 |
CN106966950A (zh) * | 2017-04-17 | 2017-07-21 | 兰州大学 | 药物中间体5‑溴吲哚的一种制备方法 |
-
2018
- 2018-06-28 CN CN201810685651.7A patent/CN108440365B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106749235A (zh) * | 2016-12-01 | 2017-05-31 | 西南大学 | 多取代喹啉并吡咯衍生物的制备方法 |
CN106966950A (zh) * | 2017-04-17 | 2017-07-21 | 兰州大学 | 药物中间体5‑溴吲哚的一种制备方法 |
Non-Patent Citations (3)
Title |
---|
BO HUANG ET AL.: ""Cu(I)/TEMPO-catalyzed aerobic oxidative synthesis of imines directly from primary and secondary amines under ambient and neat conditions"", 《TETRAHEDRON LETTERS》 * |
YAN LIU, ET AL.,: ""Synthesis of Pyrrole via a Silver-Catalyzed 1,3-Dipolar Cycloaddition/Oxidative Dehydrogenative Aromatization Tandem Reaction "", 《THE JOURNAL OF ORGANIC CHEMISTRY》 * |
ZHENG LUO ET AL.,: ""Application of Cu(I)/TEMPO/O2 Catalytic System for Aerobic Oxidative Dehydrogenative Aromatization of Pyrrolidines"", 《GREEN CHEMISTRY》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110357801A (zh) * | 2019-07-23 | 2019-10-22 | 浙江工业大学 | 一种碘催化三组分反应合成含氮五元杂环化合物的方法 |
CN110759909A (zh) * | 2019-11-19 | 2020-02-07 | 淮阴师范学院 | 一种吡咯并[2,1-a]异喹啉衍生物的制备方法 |
CN110759909B (zh) * | 2019-11-19 | 2020-11-10 | 淮阴师范学院 | 一种吡咯并[2,1-a]异喹啉衍生物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN108440365B (zh) | 2021-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110540540B (zh) | 一种催化制备二氢[1,2,4]三唑并[1,5-a]嘧啶类衍生物的方法 | |
CN103274987A (zh) | 3,3-二取代氧化吲哚衍生物及其合成方法和应用 | |
CN108440365A (zh) | 多取代吡咯衍生物的制备方法 | |
Abdollahi-Basir et al. | MIL-53 (Fe): Introduction of a new catalyst for the synthesis of Pyrimido [4, 5-d] pyrimidine derivatives under solvent-free conditions | |
Mohammadzadeh et al. | A convenient one-pot synthesis of new chromeno [3, 4-c] chromene and chromeno [3, 4-c] pyridine derivatives in the presence of high surface area of magnesium oxide | |
Ziarati et al. | Pseudo five-component process for the synthesis of functionalized tricarboxamides using CuI nanoparticles as reusable catalyst | |
CN106565583A (zh) | 多取代吡咯衍生物的制备方法 | |
CN103232462B (zh) | 香豆素-吡咯类化合物的合成方法 | |
CN102766092A (zh) | 手性螺环磷酸催化合成光学活性四氢喹啉衍生物的方法 | |
CN106518865B (zh) | 一种1-烯基中氮茚衍生物的制备方法 | |
CN113912609B (zh) | 一种天然生物碱色胺酮及其衍生物的制备方法 | |
CN114990592A (zh) | 一种电催化合成多取代噁唑的方法 | |
CN103755715B (zh) | 苯并呋喃并[2,3-c]吡啶化合物及其合成方法 | |
CN109320488B (zh) | 一种3-羟基黄酮及其衍生物的水相一锅合成方法 | |
CN113511986A (zh) | 一种芳基乙腈类衍生物的制备方法 | |
CN111559993A (zh) | 一种呋喃甲醇类化合物的制备方法 | |
CN104860836A (zh) | 一种氧化1,3-二羰基化合物的亚甲基成酮的方法 | |
CN105153126A (zh) | 一种双吲哚马来酰亚胺类化合物的制备方法 | |
Ichie et al. | Magnetic Nanoparticles Functionalized with Benzo [d] oxazole as an Efficient and Recyclable Magnetic Catalyst for the Synthesis of 1, 4-dihydropyridine Derivatives from Barbituric Acid | |
CN103274981A (zh) | 3-羟基多取代四氢吡咯衍生物的合成方法 | |
CN109833908A (zh) | 一种手性高价碘催化剂及其制备方法和应用 | |
CN113373466B (zh) | 一种β-乙酰氨基羰基化合物的电化学合成方法 | |
CN103087064B (zh) | 一种制备3-芳基中氮茚衍生物的方法 | |
CN115108985B (zh) | 4-(环己基甲基)-2,4-二甲基异喹啉-1,3(2h,4h)-二酮的合成方法 | |
CN114149447B (zh) | 一种5-单硝酸异山梨酯的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240424 Address after: 215400 No. 18, Dongfang East Road, petrochemical District, taicanggang Port Development Zone, Taicang City, Suzhou City, Jiangsu Province Patentee after: ABA Chemicals Corp. Country or region after: China Address before: 223300 No. 111 Changjiang West Road, Huaiyin District, Jiangsu, Huaian Patentee before: HUAIYIN NORMAL University Country or region before: China |